4P-Pharma

Executive Summary

4P-Pharma is a clinical-stage French biotech founded in 2014, leveraging a co-risk, co-share R&D model to develop first-in-class therapies for serious diseases with high unmet medical need. The company focuses on rapid time-to-market assets with strong intellectual property and uses expedited regulatory pathways and patient-centric trial designs. Operating in biologics, generic drugs, and small molecules, 4P-Pharma partners with academic and private institutions to accelerate drug development. With a Phase 2-stage pipeline and a private company structure, 4P-Pharma aims to translate scientific discoveries into innovative treatments while mitigating development risks through collaborative partnerships. The biotech's strategy emphasizes speed and efficiency in bringing therapies to patients, positioning it as a potential player in niche therapeutic areas.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Clinical Data Readout for Lead Candidate60% success
• Q4 2026New Partnership or Licensing Agreement50% success
• TBDRegulatory Update or Fast Track Designation45% success